BioLine Rx (XTAE:BLRX) Gross-Profit-to-Asset % : 32.88% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BioLine Rx's annualized Gross Profit for the quarter that ended in Dec. 2023 was ₪71.80 Mil. BioLine Rx's average Total Assets over the quarter that ended in Dec. 2023 was ₪218.36 Mil. Therefore, BioLine Rx's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 32.88%.

BioLine Rx Gross-Profit-to-Asset % Historical Data

The historical data trend for BioLine Rx's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Gross-Profit-to-Asset % Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.58

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	32.88

Competitive Comparison of BioLine Rx's Gross-Profit-to-Asset %

For the Biotechnology subindustry, BioLine Rx's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Gross-Profit-to-Asset % falls into.

BioLine Rx Gross-Profit-to-Asset % Calculation

BioLine Rx's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	4.144	/	( (285.649	+	239.057)	/ 2 )
	=	4.144	/	262.353
	=	1.58 %

BioLine Rx's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	71.8	/	( (197.659	+	239.057)	/ 2 )
	=	71.8	/	218.358
	=	32.88 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

BioLine Rx Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.